Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $652 Billion
  • Q2 2025

Adar1 Capital Management, LLC has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $652 Billion distributed in 210 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Keros Therapeutics, Inc. with a value of $71.9B, Protagonist Therapeutics, Inc with a value of $52.4B, Ea Series Trust with a value of $38B, Zai Lab LTD with a value of $29.7B, and Abivax Sa with a value of $23.5B.

Examining the 13F form we can see an increase of $113B in the current position value, from $539B to 652B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $652 Billion
Healthcare: $418 Billion
ETFs: $56.4 Billion
Basic Materials: $135 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$521M
$622 Million 0.1% of portfolio
441,176
Q2 2025 Added 65.75%
$783M
$601 Million 0.09% of portfolio
34,124
Q2 2025 New
$227B
$557 Million 0.09% of portfolio
7,040
Q2 2025 New
Lexeo Therapeutics Inc
-
$583 Million 0.09% of portfolio
-
Q2 2025 Reduced 14.87%
$474M
$608 Million 0.09% of portfolio
63,424
Q2 2025 Added 48.19%
$3.06B
$583 Million 0.09% of portfolio
13,366
Q2 2025 Added 33.66%
-
$567 Million 0.09% of portfolio
-
Q2 2025 Added 158.59%
$0
$503 Million 0.08% of portfolio
10,000
Q3 2024 Reduced 81.13%
$2.04B
$500 Million 0.08% of portfolio
35,716
Q2 2025 Added 157.45%
Grace Therapeutics Inc
-
$525 Million 0.08% of portfolio
-
Q2 2025 Reduced 48.58%
Spyre Therapeutics Inc
-
$510 Million 0.08% of portfolio
-
Q2 2025 Added 126.51%
$970M
$524 Million 0.08% of portfolio
40,000
Q2 2025 Added 100.0%
$63M
$530 Million 0.08% of portfolio
204,497
Q2 2025 New
Avalo Therapeutics Inc
-
$523 Million 0.08% of portfolio
-
Q2 2025 Added 947.3%
$126B
$483 Million 0.07% of portfolio
10,000
Q2 2025 New
Neurogene Inc
-
$443 Million 0.07% of portfolio
-
Q2 2025 Added 6.09%
Nabors Energy Transition Cor
-
$443 Million 0.07% of portfolio
-
Q4 2024 Reduced 33.39%
Kiora Pharmaceuticals Inc
-
$481 Million 0.07% of portfolio
-
Q2 2025 Reduced 14.15%
$488M
$367 Million 0.06% of portfolio
53,349
Q2 2025 Reduced 89.12%
$15.5B
$422 Million 0.06% of portfolio
2,500
Q2 2025 Reduced 41.18%
$779B
$390 Million 0.06% of portfolio
500
Q2 2025 Reduced 16.67%
$200M
$361 Million 0.06% of portfolio
168,600
Q2 2025 Reduced 40.13%
Polypid LTD
-
$367 Million 0.06% of portfolio
-
Q2 2025 Added 29.81%
$55.9M
$372 Million 0.06% of portfolio
122,690
Q4 2024 New
Nektar Therapeutics
-
$408 Million 0.06% of portfolio
-
Q2 2025 New
$71.9M
$417 Million 0.06% of portfolio
143,917
Q2 2025 Reduced 82.04%
$7.69B
$319 Million 0.05% of portfolio
1,054
Q2 2025 Reduced 29.26%
Structure Therapeutics Inc
-
$311 Million 0.05% of portfolio
-
Q2 2025 Reduced 57.89%
$2.54B
$294 Million 0.05% of portfolio
17,000
Q1 2025 Added 13.33%
$428M
$355 Million 0.05% of portfolio
31,200
Q2 2025 Added 47.17%
Agriculture & Nat Sol Acq CO
-
$294 Million 0.05% of portfolio
-
Q2 2025 Reduced 42.5%
$978M
$310 Million 0.05% of portfolio
27,285
Q2 2025 Reduced 9.31%
Therapeuticsmd Inc
-
$243 Million 0.04% of portfolio
-
Q2 2025 Reduced 22.56%
$70.5M
$236 Million 0.04% of portfolio
142,958
Q3 2024 Added 53.79%
$10.3B
$269 Million 0.04% of portfolio
4,900
Q1 2025 New
$184M
$249 Million 0.04% of portfolio
79,945
Q2 2025 Added 5.82%
$361M
$269 Million 0.04% of portfolio
26,937
Q2 2025 Reduced 73.36%
$8.6B
$292 Million 0.04% of portfolio
2,750
Q2 2025 New
Iron Horse Acquisitions Corp
-
$258 Million 0.04% of portfolio
-
Q3 2024 New
$11.2B
$242 Million 0.04% of portfolio
1,402
Q1 2025 Reduced 98.04%
$17.6M
$230 Million 0.04% of portfolio
351,094
Q4 2024 Reduced 6.08%
$4.21B
$255 Million 0.04% of portfolio
12,000
Q2 2025 New
$233M
$279 Million 0.04% of portfolio
227,228
Q1 2025 Reduced 23.13%
$653M
$220 Million 0.03% of portfolio
23,063
Q2 2025 Reduced 23.38%
Bicara Therapeutics Inc
-
$213 Million 0.03% of portfolio
-
Q2 2025 New
$571M
$164 Million 0.03% of portfolio
30,000
Q2 2025 New
$611M
$198 Million 0.03% of portfolio
34,300
Q2 2025 Added 37.2%
$996M
$177 Million 0.03% of portfolio
35,000
Q2 2025 Added 133.33%
$546M
$182 Million 0.03% of portfolio
28,023
Q1 2025 Reduced 47.15%

Summary

  • Portfolio
  • No. of Stocks 210
  • Current Value $652 Billion
  • Prior Value $539 Billion
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 43 stocks
  • Additional Purchases 61 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 53 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email